Treatment of Essential Thrombocythemia in Age ≤60 Years with No Thrombosis History and JAK2 Wild-Type (Triple-Negative) Status
Patients with essential thrombocythemia who are aged 60 years or younger, have no prior thrombosis, a JAK2 wild-type profile, no cardiovascular risk factors, and triple-negative mutational status (negative for JAK2, CALR, and MPL mutations) represent a very low-risk sub-population. Thrombosis risk stratification is central to determining their management approach.
Clinical Scenario
Age ≤60 years · No history of thrombosis · JAK2 wild-type · No cardiovascular risk factors · Triple-negative (no JAK2, CALR, or MPL mutation)
Management Approach
In this very low-risk presentation, the evidence-based approach does not call for initiating pharmacological therapy. The complete protocol — including the structured follow-up framework and the thresholds that would prompt reassessment — is available below.
References
DOI: 10.1002/ajh.27216
Figure 5 outlines our general treatment approach in ET, which starts with thrombosis risk stratification: very low (age ≤60 years, no thrombosis history, JAK2 wild-type), low (same as very low but JAK2 mutation present), intermediate (age >60 years, no thrombosis history, JAK2 wild-type), and high (thrombosis history present or age >60 years with JAK2 mutation).
Thrombosis risk in very low risk patients with triple-negative driver mutational status is too low to warrant the need for any form of therapy, but once-daily aspirin therapy is advised in the presence of either CV risk factors or CALR-1/MPL mutations.
Very low-risk patients with ET might not require any therapy, unless in the presence of CV risk factors or CALR-1/MPL mutations, where once-daily low-dose aspirin is advised (Figure 5).
View source ↗